Longeveron shares soar 105% after Phase I results of new Alzheimer's drug

Article source: Medical Cube Info

Author: Pickup

On March 31, Longeveron announced that the journal Alzheimer's & Dementia® published results from a Phase I trial in patients with mild Alzheimer's disease (AD)

Affected by the news, the company's shares rose 105%

Lomecel-B is an allogeneic, bone marrow-derived medicinal signaling cell (MSC) product

The article, "Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer's disease," details the results of the Lomecel-B study

The study met its primary endpoint - safety

Other exploratory findings include:

The Mini-Cognitive Status Evaluation Scale (MMSE), which is used to assess cognitive status, showed a slower decline in scores in the low-dose Lomecel-B group compared with the placebo group

Based on the findings, Longeveron opened a new, larger, double-blind, randomized, placebo-controlled Phase II study to evaluate the effects of single and multiple doses of Lomecel-B in the treatment of mild AD

In addition to being used to treat AD, Lomecel-B is also being developed for the treatment of frail aging, hypoplastic left heart syndrome, and acute respiratory distress syndrome caused by COVID-19